Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

about

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

Item

http://www.wikidata.org/entity/Q55062363

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

@en

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

@nl

type

Item

label

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

@en

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

@nl

prefLabel

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

@en

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

@nl

P1476

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

@en

P2093

Aritsune Ooho

http://www.w3.org/2001/XMLSchema#string

Koichi Azuma

http://www.w3.org/2001/XMLSchema#string

Motohiro Esaki

http://www.w3.org/2001/XMLSchema#string

Shigeo Nakamura

http://www.w3.org/2001/XMLSchema#string

Shotaro Nakamura

http://www.w3.org/2001/XMLSchema#string

Shunichi Yanai

http://www.w3.org/2001/XMLSchema#string

Takanari Kitazono

http://www.w3.org/2001/XMLSchema#string

Takayuki Matsumoto

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Treatment of radiation-induced hemorrhagic duodenitis with argon plasma coagulation.

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

A unique bleeding-related complication of sorafenib, a tyrosine kinase inhibitor, in advanced hepatocellular carcinoma: a case report.

Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.

P2888

s12328-015-0566-y

P304

116-119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12328-015-0566-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039620070

http://www.w3.org/2001/XMLSchema#string

P698

25832768

http://www.w3.org/2001/XMLSchema#string